S H O C K C A R I O G E N I C O2

30
ACC/AHA 2007 STEMI Guidelines Focused Update UNIVERSIDAD RICARDO PALMA FACULTAD DE MEDICINA HUMANA V CURSO INTERNACIONAL DE ACTUALIZACIÓN EN MEDICINA Y CIRUGIA – IV JORNADA DE EDUCACIÓN MÉDICA UNIVERSITARIA CONFERENCIA: “SHOCK CARDIOGÉNICO” DOCTOR ALFREDO PALACIO I N C A P U E E S INSTITUTO NACIONAL DE CARDIOLOGIA FACULTAD DE MEDICINA “ALFREDO PALACIO” “ENRIQUE ORTEGA MOREIRA” GUAYAQUIL – ECUADOR

Transcript of S H O C K C A R I O G E N I C O2

Page 1: S H O C K  C A R I O G E N I C O2

ACC/AHA 2007 STEMI Guidelines Focused Update

UNIVERSIDAD RICARDO PALMAFACULTAD DE MEDICINA HUMANA

V CURSO INTERNACIONAL DE ACTUALIZACIÓN EN MEDICINA Y CIRUGIA – IV JORNADA DE EDUCACIÓN MÉDICA UNIVERSITARIA

CONFERENCIA:

“SHOCK CARDIOGÉNICO”

DOCTORALFREDO PALACIO

I N C A P U E E SINSTITUTO NACIONAL DE CARDIOLOGIA FACULTAD DE MEDICINA “ALFREDO PALACIO” “ENRIQUE ORTEGA MOREIRA”

GUAYAQUIL – ECUADOR

Page 2: S H O C K  C A R I O G E N I C O2

SHOCK CARDIOGENICO

•DEFINICION:•EVIDENCIA CLINICA DE HIPOPERFUSION•CON PRESION ARTERIAL SISTOLICA < 90 mm Hg > 30 min•NECESIDAD DE TERAPIA PARA MANTENER PAS > DE 90 mmHg•IC < 2.2 L/ min / m2•PCP (en cuña) > 15 mm Hg

THE SHOCK TRIAL JAMA 2001; 285: 190-2

Page 3: S H O C K  C A R I O G E N I C O2

SHOCK CARDIOGENICO

PREREPERFUSION REPERFUSION

PREVALENCIA

EN IMA

20% 5 – 7 %

MORTALIDAD 80% 40% *

SOBREVIDA – IH -INTRAHOSPITALARIA + / IABP

20-50%

70 %

* SIGUE SIENDO LA 1ª CAUSA DE

MUERTE – IH – EN EL IMA(TAMI) I TRIAL CIRCULATION 1988; 77: 1090-90

NEJM 1991; 325: 1117-22

JACC 1992; 20: 1982-9

Page 4: S H O C K  C A R I O G E N I C O2

SHOCK CARDIOGENICO

• CAUSAS– EXTENSION DEL IMA (40% VI)– IMA DE VENTRICULO DERECHO– RM AGUDA (RUPTURA DE MP)– CIV AGUDA– RUPTURA DE PARED LIBRE– TAPONAMIENTO CARDIACO

Page 5: S H O C K  C A R I O G E N I C O2

SHOCK CARDIOGENICO

• PRIMER RX– LIMITAR TAMAÑO DEL IMA– RESTABLECER REPERFUSION

CORONARIA– CONTROLAR RESPUESTAS

INJURIOSAS» ACTIVIDAD SIMPATICA» SISTEMA SRA» RESISTENCIA PERIFERICA» POST CARGA

Page 6: S H O C K  C A R I O G E N I C O2

SHOCK CARDIOGENICOCURVAS DE PRESION Y DE PERFUSION CORONARIA

Page 7: S H O C K  C A R I O G E N I C O2

SHOCK CARDIOGENICOIMA

• Injuria Miocardica Irreversible 15 - 20 min• Injuria completa area de riesgo 4 - 6 Hrs• Mayor magnitud del daño 2 - 3 Hrs• Restauración del flujo para

obtener mayor beneficio 1 - 2 Hrs• Hipóteis de arteria abierta

flujo normal mortalidad• Tamaño de infarto lo anterior mas colaterales

Page 8: S H O C K  C A R I O G E N I C O2

Emergency Management of Complicated STEMIEmergency Management of Complicated STEMI

Administer• Fluids• Blood transfusions• Cause-specific interventionsConsider vasopressors

Arrhythmia

Bradycardia Tachycardia

Systolic BPGreater than 100 mm Hg

Systolic BP 70 to 100 mm Hg

NO signs/symptomsof shock

Systolic BP70 to 100 mm HgSigns/symptoms

of shock

Systolic BP less than 70 mm Hg

Signs/symptoms of shock

Dobutamine2 to 20

mcg/kg per minute IV

Low Output -Cardiogenic Shock

Nitroglycerin10 to 20 mcg/min IV

Dopamine5 to 15

mcg/kg per minute IV

Norepinephrine0.5 to 30 mcg/min IV

Hypovolemia

Administer• Furosemide IV 0.5 to 1.0 mg/kg• Morphine IV 2 to 4 mg• Oxygen/intubation as needed• Nitroglycerin SL, then 10 to 20 mcg/min IV if SBP greater than 100 mm Hg• Dopamine 5 to 15 mcg/kg per minute IV if SBP 70 to 100 mm Hg and signs/symptoms of shock present• Dobutamine 2 to 20 mcg/kg per minute IV if SBP 70 to 100 mm Hg and no signs/symptoms of shockF

irs

t li

ne

of

ac

tio

nS

ec

on

d l

ine

of

ac

tio

nT

hir

d l

ine

of

ac

tio

n

ACC/AHA Guidelines for Patients With ST-Elevation

Myocardial Infarction

Check Blood Pressure

Clinical signs: Shock, hypoperfusion, congestive heart failure, acute pulmonary edemaMost likely major underlying disturbance?

Further diagnostic/therapeutic considerations (should be considered in nonhypovolemic shock)Diagnostic Therapeutic♥ Pulmonary artery catheter ♥ Intra-aortic balloon pump♥ Echocardiography ♥ Reperfusion/revascularization♥ Angiography for MI/ischemia ♥ Additional diagnostic studies

Acute Pulmonary Edema

Check Blood Pressure

Systolic BP Greater than 100 mm Hg

and not less than 30 mm Hg below baseline

ACE InhibitorsShort-acting agent such as

captopril (1 to 6.25 mg)

Circulation 2000;102(suppl I):I-172-I-216.

Page 9: S H O C K  C A R I O G E N I C O2

All-Cause Mortality

Years

Pro

bab

ilit

y o

f Even

t

0

0.05

0.1

0.15

0.2

0.25

0.3

0 1 2 3

0.35

0.4

4

ACE-I

Placebo

ACE-I 2995 2250 1617 892 223

Placebo 2971 2184 1521 853 138

Flather MD, et al. Lancet. 2000;355:1575–1581

OR: 0.74 (0.66–0.83)OR: 0.74 (0.66–0.83)

ACE-I: 702/2995 (23.4%)ACE-I: 702/2995 (23.4%)

Placebo: 866/2971 (29.1%)Placebo: 866/2971 (29.1%)

TRACEEchocardiographicEF 35%

AIREClinical and/or radiographic signs of HF

SAVERadionuclideEF 40%

Page 10: S H O C K  C A R I O G E N I C O2

Nitrates should not be administered to patients with:

Nitrates should not be administered to patients who have received a phosphodiesterase inhibitor for erectile dysfunction within the last 24 hours (48 hours for tadalafil).

• systolic pressure < 90 mm Hg or ≥ to 30 mm Hg below baseline

• severe bradycardia (< 50 bpm)• tachycardia (> 100 bpm) or• suspected RV infarction.

When NOT to give NitroglycerinWhen NOT to give Nitroglycerin

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

SHOCK CARDIOGENICOIMA

Page 11: S H O C K  C A R I O G E N I C O2

EVIDENCE GRADING

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

A B CBENEFICIAL HARMFULBENEFICIAL HARMFUL

RANDOMIZED EXPERT OPINION

SHOCK CARDIOGENICOIMA

Page 12: S H O C K  C A R I O G E N I C O2

Cardiogenic Shock

1-2 vessel CAD Moderate 3-vessel CAD Severe 3-vessel CAD Left main CAD

PCI IRA PCI IRA Immediate CABG

Staged Multivessel PCI

Staged CABGCannot be performed

Early Shock, Diagnosed on Hospital Presentation

Delayed Onset Shock Echocardiogram to Rule Out

Mechanical Defects

Cardiac Catheterization and Coronary Angiography

IABP

Fibrinolytic therapy if all of the following are present:

1. Greater than 90 minutes to PCI2. Less than 3 hours post STEMI

onset3. No contraindications

Arrange prompt transfer to invasive procedure-capable center

Arrange rapid transfer to invasive procedure-capable center

PCI for Cardiogenic ShockPCI for Cardiogenic Shock

Page 13: S H O C K  C A R I O G E N I C O2

SHOCK CARDIOGENICO

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

< 75 AÑOS• ST • BCRI• SHOCK < 36 HS DEL IMA• INTERVENCION < 18 HORAS

REVASCULARIZACION TEMPRANA

CLASE IA

BALON DE CONTRAPULSACION AORTICO (IABP)

Page 14: S H O C K  C A R I O G E N I C O2

14

ACC/AHA 2007 STEMI Guidelines Focused Update

SHOCK CARDIOGENICO

STEMI + PAS < 90 mm HgPAm < 30 mm Hg

CLASE IB

BALON INTRAORTICO DE CONTRAPULSACION (IABP)

STEMI + ESTADO DE BAJO GASTO CARDIACO STEMI + SHOCK SIN RESPUESTA FARMACOLOGICA

STEMI + DOLOR PRECORDIAL ISQUEMIA RECURRENTE INESTABILIDAD HEMODINAMICA FUNCION VENTRICULAR DEPRIMIDA AREA MIOCARDICA DE RIESGO GRANDEIACB + CAT + CIRUGIA

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

CLASE IC

Page 15: S H O C K  C A R I O G E N I C O2

SHOCK CARDIOGENICO

STEMI + TAQUICARDIA VENTRICULAR POLIMORFA

CLASE II a

BALON INTARORTICO DE CONTRAPULSACION (IABP)

STEMI + ICC

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

Page 16: S H O C K  C A R I O G E N I C O2

ACC/AHA 2007 STEMI Guidelines Focused Update

A C P

Page 17: S H O C K  C A R I O G E N I C O2

ACP PRIMARIA O DE RESCATE EN STEMI:ACP PRIMARIA O DE RESCATE EN STEMI:

DEBE REALIZARSE –IB-

•en pacientes severa (ICC) (Killip clase 3)

• con Sx < 12 horas

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

La ACP Primaria debe realizarse -IA- • en pacientes < 75 años •con elevación ST o BCRI • SHOCK <36 horas post MI, • ACP realizable <primeras 18 horas del shock.En pacientes >75 años: -IIa B-

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

SHOCK CARDIOGENICOIMA

Page 18: S H O C K  C A R I O G E N I C O2

APC POSTERIOR A FIBRINOLISISAPC POSTERIOR A FIBRINOLISIS

APC debe ser realizada en pacientes con: Evidencia objetiva de IMA recurrente

Isquemia miocardica moderada o severa, ya sea espontanea o provocada, durante la recuperacion STEMI

Shock cardiogenico o inestabilidad hemodinamica.

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

SHOCK CARDIOGENICOIMA

Page 19: S H O C K  C A R I O G E N I C O2

ACC/AHA 2007 STEMI Guidelines Focused Update

FIBRINOLÍSISREPERFUSIÓN

Page 20: S H O C K  C A R I O G E N I C O2

SHOCK CARDIOGENICO

FIBRINOLISIS–CUANDO INTERVENCION ESTA CONTRAINDICADA

MONITOREO HEMODINAMICO INTRAARTERIAL

ECOCARDIOGRAFIA–(EVIDENCIAR COMPLICACIONES MECANICAS)

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

CLASE I

Page 21: S H O C K  C A R I O G E N I C O2

21

ACC/AHA 2007 STEMI Guidelines Focused Update

SHOCK CARDIOGENICO

REVASCULARIZACION DE EMERGENCIA

ESTABILIZACION MEDICA INICAL

MORTALIDAD 30 DIAS

46.7% 50.0%

6 A 12 MESES 53.3% 66.4%

THE SHOCK TRIAL

(P=0.11)

(P<0.03)

REVASCULARIZACION

Page 22: S H O C K  C A R I O G E N I C O2

SHOCK CARDIOGENICO

CATETER PULMONAR

REVASCULARIZACION TEMPRANA• < 75 AÑOS• ST • BCRI• SHOCK < 36 HS DEL IMA• INTERVENCION < 18 HORAS• > 75 AÑOS INDICACION IIaB

CLASE II

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

Page 23: S H O C K  C A R I O G E N I C O2

Right Ventricular InfarctionClinical findings:

Shock with clear lungs, elevated JVPKussmaul sign

Hemodynamics: Increased RA pressure (y descent)Square root sign in RV tracing

ECG:ST elevation in R sided leads

Echo:Depressed RV function

Rx:Maintain RV preloadLower RV afterload (PA---PCW)Inotropic supportReperfusion

V4R

Modified from Wellens. N Engl J Med 1999;340:381.

Page 24: S H O C K  C A R I O G E N I C O2

SHOCK CARDIOGENICO

EKG + V4R ECOCARDIOGRAMA

CLASE I

SOSPECHA DE IMA VD STEMI + INESTABILIDAD HEMODINAMICAINFERIOR

REPERFUSION TEMPRANA ACP CORREGIR BRADICARDIA Y ASINCRONIA AV PRECARGA DERECHA

CARGA INICAL RESPUESTA POSITIVAOPTIMIZAR VOLUMENPV < NORMAL

POSCARGA DERECHA OPTIMIZAR FUNCION V IZQ.

ASISTENCIA INOTROPICACUANDO SOBRECARGA DE VOLUMEN ES

INSUFICIENTE

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

Page 25: S H O C K  C A R I O G E N I C O2

Ventricular Septal Rupture

Mitral Regurgitation(Pap. M. dysfunction)

Incidence 1-2% 1-6% 1-2%Timing 3-5 d p MI 3-6 d p MI 3-5 d p MIPhy Exam murmur 90% JVD, EMD murmur 50%Thrill Common No RareEcho Shunt Peric. Effusion Regurg. JetPA cath O2 step up Diast Press Equal. c-v wave in PCW

Images:Courtesy of W D Edwards (Mayo Foundation)Data: Lavocitz. CV Rev Rpt 1984;5:948; Birnbaum. NEJM 2002;347:1426.

Free WallRupture

Page 26: S H O C K  C A R I O G E N I C O2

SHOCK CARDIOGENICO

RUPTURA DE MUSCULO PAPILARCIRUGIA URGENTE

REGURGITACION MITRAL

CONCOMITANTE CABG

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

Mitral Regurgitation(Pap. M. dysfunction)

Page 27: S H O C K  C A R I O G E N I C O2

SHOCK CARDIOGENICO

CIRUGIA URGENTE

RUPTURA SEPTAL O DE PARED LIBRE

CABG

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIIIVentricular

Septal Rupture

Page 28: S H O C K  C A R I O G E N I C O2

SHOCK CARDIOGENICO

STEMI + AV + ARRITMIA INTRATABLE Y/O SHOCKANEURISMECTOMIA + CABC

ANEURISMA VENTRICULAR

III IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIII IIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII

Page 29: S H O C K  C A R I O G E N I C O2

31

ACC/AHA 2007 STEMI Guidelines Focused Update

Atacado de fiebres un indio de Loja llamado Pedro de Leyva, bebió, para calmar los ardores de la sed, del agua de un remanso, en cuyas orillas crecían algunos árboles de quina … Con su descubrimiento vino a Lima y lo comunicó a un jesuita, el que, realizando la feliz curación de la virreina, prestó a la Humanidad mayor servicio que el fraile que inventó la pólvora.

Mendiburo dice que, al principio, encontró el uso de la quina fuerte oposición en Europa, y que en Salamanca se sostuvo que caía en pecado mortal el médico que la recetaba, pues sus virtudes eran debidas a pacto de los peruanos con el diablo.

Page 30: S H O C K  C A R I O G E N I C O2

32

ACC/AHA 2007 STEMI Guidelines Focused Update

PAZ MUNDIAL